Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: Int J Gynecol Cancer. 2014 Feb;24(2):218–225. doi: 10.1097/IGC.0000000000000056

Figure 1.

Figure 1

SRC and paxillin protein expression in the IGROV1 cells after treatment with dasatinib and/or chemotherapeutic agents. (A) tSRC protein expression decreased significantly after treatment with single-agent dasatinib, and dasatinib in combination with docetaxel and topotecan. (B). pSRC levels dramatically decreased in the presence of any of the single-agent treatments. (C) The ratio of pSRC/tSRC was reduced after treatment with dasatinib alone (71%), gemcitabine (40%), doxorubicin (96%), docetaxel (59%), and topotecan (58%). (D) t-paxillin protein expression decreased after treatment with dasatinib alone as well as in combination with gemcitabine, docetaxel, or topotecan. (E) p-paxillin levels were dramatically decreased after treatment with any agent. (F) The ratio of p-paxillin/t-paxillin was reduced by with dasatinib alone (77%), gemcitabine (52%), docetaxel (83%), and topotecan (80%). All experiments were performed in duplicate. * p < 0.05 compared to controls. ^ p < 0.05 compared to respective chemotherapy.